

Methodological Note for Disclosures of Transfer of Value

Prepared March 2023

This note describes the methodology used by Leadiant Biosciences Ltd to identify, collate and report transfers of value disclosures, in compliance with the Association of British Pharmaceutical Industry (ABPI) code. The ABPI code requires disclosures of all transfers of value to healthcare organisations (HCOs), healthcare practitioners (HCPs) and other relevant decision makers (ORDMs) in the year previous to year of disclosure. This note will report on transfers of value made in the period January 1st 2022 and December 31st, 2022. All transfers of value in Europe will be disclosed.

Identification of Transfers of Value:

To identify all transfers of value, all payments for Grants, Sponsorship, Donations and Consultancy fees made in 2022 by Leadiant Biosciences UK were screened, and those fitting the requirements of transfers of value were included. These were cross-checked against the compliance approval system in the company for the period between 1st of January 2022 and 31st December, 2022. Grants are defined as unsolicited requests for funds and/or product for investigator-initiated research or projects for which progress reports of the project milestones are required for payment. Sponsorship refers to transfers towards the organization of scientific conferences. Donation refers to any transfers of value that do not require specific projects and are given to a scientific society or patient organization.

Data Privacy

Leadiant Biosciences discloses the data on the basis of legitimate interests. Consent to disclose is included in the grant/sponsorship agreements but consent is not specifically confirmed prior to publication.

Transfers of Value

All transfers of value specified in our disclosure are denominated in pounds sterling. If the original payment was made in Euros, we have converted the amount into GBP using the



foreign exchange rate on closing on the day of payment. Amounts disclosed in GBP may therefore vary from the exact amount paid in the local currency. Where a transfer of value is made to a healthcare professional indirectly via a healthcare organisation, where possible Leadiant aims to disclose the transfers of value made to the healthcare professional that the payment benefits, as per the ABPI code. Where a contract for activities covered for a particular transfer of value runs over multiple years and thus disclosure cycles, Leadiant aims to disclose any transfer of value in the year that it was actually paid. Leadiant discloses the exact amount paid to the HCP, HCO or ORDM. This may include VAT, if VAT was included on the invoice. For transfers of value where product is provided free of cost for research, the amount disclosed is calculated using the unit list price in the country concerned.

All transfers of value are disclosed on the Disclosure UK portal, irrespective of where the recipient of the transfer of value resides.

Payments made in 2022.

No payments to individual HCPs were identified for the year 2022.

No Donations were identified for the year 2022.

Grants and Sponsorships given to HCOs were to support organization of scientific congresses, meetings, and investigator sponsored research. Installment payment for one multi-year contract has been disclosed in 2022. There were no over the counter or medical device transfers of value in 2022.